Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parathyroid hormone CriticalSorb is an intranasal formulation of parathyroid hormone (PTH 1-34/teriparatide) that utilizes CriticalSorb™ absorption enhancer technology to enable nasal delivery. This formulation was developed as an alternative to injectable parathyroid hormone products, allowing for nasal administration instead of daily injections. The CriticalSorb™ technology (polyethylene glycol (15)-hydroxystearate) enhances drug transport across nasal mucosal membranes through both transcellular and paracellular mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on parathyroid hormone CriticalSorb.